Trials comparing fexofenadine with older second- generation antihistamines have yielded mixed results, suggesting that there may be differences between second-generation agents. In the 14-day study by van Cauwenberge and Juniper,74 688 subjects (56% female, 44% male; mean age, 31 years [range, 12–75 years]) with a ≥2-year history of moderate to severe SAR were randomized to receive once-daily fexofenadine 120 mg, loratadine 10 mg, or placebo. Fexofenadine, but not loratadine, was associated with significant improvements in 24-hour reflective nasal congestion scores compared with placebo (P ≤ 0.05).